miR-193b-3p inhibits PLAU gene expression in patients with in-stent restenosis
| Autor: | Ghasem Ghasempour, Noorabad-Ghahroodi Faezeh, Azim Shams Biranvand, Naser Kakavandi, Shima Rezaee, Mohammad Najafi, Mohsen Khosravi, Amirfarhangi Abdollah |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Neointimal hyperplasia medicine.medical_specialty business.industry medicine.medical_treatment Monocyte Stent medicine.disease Peripheral blood mononuclear cell Coronary arteries 03 medical and health sciences Stenosis 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Restenosis 030220 oncology & carcinogenesis Angioplasty Internal medicine Genetics medicine Cardiology business Genetics (clinical) |
| Zdroj: | Meta Gene. 22:100602 |
| ISSN: | 2214-5400 |
| DOI: | 10.1016/j.mgene.2019.100602 |
| Popis: | Background The coronary artery restenosis is a main problem in patients undergoing the stent implantation and angioplasty. The neointimal hyperplasia is one of the major causes for re-narrowing of blood vessels. Based on the prediction data, the aim of this study was to evaluate the PBMC miR-193b-3p and PLAU expression levels in patients with the stenosis of coronary arteries. Methods A total of sixty three individuals undergoing coronary artery angiography including In-stent restenosis (n = 21, restenosis>70%), Stent non-restenosis (n = 21, stenosis Results The miR-193b-3p was predicted to suppress the PLAU gene. The PLAU/miR193b-3p expression ratio was significantly increased in patients with In-stent restenosis conversely with control and Stent non-restenosis groups (P Conclusion The findings might suggest that the increase of monocyte PLAU gene expression is probably under control of miR-193b-3p. However, more investigations are needed to support the results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect